stoxline Quote Chart Rank Option Currency Glossary
Palatin Technologies, Inc. (PTN)
1.87  0.04 (2.19%)    05-30 16:00
Open: 1.85
High: 1.88
Volume: 50,285
Pre. Close: 1.83
Low: 1.79
Market Cap: 30(M)
Technical analysis
2024-05-30 4:43:55 PM
Short term     
Mid term     
Targets 6-month :  2.53 1-year :  2.89
Resists First :  2.16 Second :  2.48
Pivot price 2.08
Supports First :  1.65 Second :  1.38
MAs MA(5) :  1.91 MA(20) :  2.08
MA(100) :  2.5 MA(250) :  2.31
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  6 D(3) :  9.3
RSI RSI(14): 43.2
52-week High :  5.65 Low :  1.42
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PTN ] has closed above bottom band by 20.2%. Bollinger Bands are 48.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.9 - 1.91 1.91 - 1.92
Low: 1.76 - 1.78 1.78 - 1.79
Close: 1.85 - 1.87 1.87 - 1.89
Company Description

Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.

Headline News

Tue, 28 May 2024
Palatin Technologies (NYSEAMERICAN:PTN) Share Price Crosses Above 200 Day Moving Average of $0.00 - Defense World

Mon, 27 May 2024
Introducing Palatin Technologies (NYSEMKT:PTN), A Stock That Climbed 69% In The Last Three Years - Yahoo Movies UK

Mon, 20 May 2024
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance

Wed, 15 May 2024
Palatin Technologies Inc. Q3 Loss Decreases - Nasdaq

Wed, 15 May 2024
Palatin Technologies, Inc. (PTN) Q3 2024 Earnings Call Transcript - Seeking Alpha

Thu, 02 May 2024
Palatin stock gains as FDA OKs obesity trial (NYSE:PTN) - Seeking Alpha

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 0 (M)
Shares Float 14 (M)
Held by Insiders 1.317e+007 (%)
Held by Institutions 3.9 (%)
Shares Short 748 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -3.053e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -290.1 %
Return on Assets (ttm) -99.2 %
Return on Equity (ttm) -1 %
Qtrly Rev. Growth 6.09e+006 %
Gross Profit (p.s.) 156.26
Sales Per Share 455.15
EBITDA (p.s.) -2e+007
Qtrly Earnings Growth -2.2 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -26 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow -4.16
Stock Dividends
Dividend 0
Forward Dividend 629840
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android